Skip to main content
Skip to content
Case File
kaggle-ho-024637House Oversight

Executive Summary on Global Cannabis Consumer Market Size

Executive Summary on Global Cannabis Consumer Market Size The passage provides generic market estimates and projections for legal and illegal cannabis markets without mentioning any specific individuals, companies, financial transactions, or government actions that could be investigated. It lacks actionable leads, novel revelations, or connections to high‑ranking officials, making it low‑value for investigative purposes. Key insights: UNODC estimates global illegal cannabis market at $113 billion in 2003.; RAND estimated U.S. illegal cannabis market at $40 billion in 2010, projected $48 billion today.; Projection that legal cannabis industry could double the size of the illegal market.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024637
Pages
1
Persons
1
Integrity
No Hash Available

Summary

Executive Summary on Global Cannabis Consumer Market Size The passage provides generic market estimates and projections for legal and illegal cannabis markets without mentioning any specific individuals, companies, financial transactions, or government actions that could be investigated. It lacks actionable leads, novel revelations, or connections to high‑ranking officials, making it low‑value for investigative purposes. Key insights: UNODC estimates global illegal cannabis market at $113 billion in 2003.; RAND estimated U.S. illegal cannabis market at $40 billion in 2010, projected $48 billion today.; Projection that legal cannabis industry could double the size of the illegal market.

Tags

kagglehouse-oversightcannabismarket-analysisillegal-marketlegalizationindustry-outlook

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
CHAPTER | Executive Summary = Global Cannabis Consumers Cannabis has mass consumer appeal around the world. Millions of people use cannabis recreationally. Millions more use it medicinally. In aggregate, across all state medical cannabis laws in the United States, cannabis is legally recognized as a form of therapy or medicine for more than 50 medical conditions, including Alzheimer’s disease, anorexia, arthritis, cancer, chronic pain, epilepsy and post-traumatic stress disorder. Similar to the alcohol and pharmaceutical markets, we believe that the total addressable consumer market for cannabis consists of a significant portion of the global adult population. Cannabis is the most widely cultivated, produced, trafficked and consumed drug worldwide, according to the United Nations Office on Drugs and Crime (UNODC). In 2003, the UNODC estimated that the global illegal cannabis market was $113 billion, with 160 million consumers. The UNODC continues to estimate the number of cannabis users worldwide and recently estimated that 183 million people globally between the ages of 15 and 64, or more than 4% of this age group, con- sumed cannabis in 2015. In 2010, the RAND Corporation (RAND) estimated that the U.S. illegal cannabis market was $40 billion. Adjusting this estimate solely for inflation and population growth, the U.S. illegal market would now be approximately $48 billion. Both the UNODC and RAND acknowledge the challenges inherent in studying an illegal con- sumer market, and both allow significant room for error in their estimates. However approximate, their estimates make clear that there is significant global demand for cannabis. Less clear is how quickly illegal markets will transition to legal markets, as well as the extent to which legalization may increase overall demand. We believe that the growth of the global legal cannabis industry will be driven by increasing pen- etration in largely untapped “mainstream” consumer markets, and that the legal industry could grow to more than two times the estimated size of the current illegal market. We believe that cannabis will eventually become federally legal in the United States, for recreational enjoyment by adults and for use in a broad range of safe drugs and therapeutic products. After U.S. federal legalization, we believe that © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 1

Related Documents (6)

House OversightOtherNov 11, 2025

Bill Siegel email chain discussing 'The Control Factor' and anti‑Islamic conspiracy narrative

The passage is an internal email and interview transcript promoting a conspiratorial worldview about 'Islamic Enemy' and 'Civilization Jihad.' It mentions Jeffrey Epstein as a sender but provides no c Email originates from Jeffrey Epstein's address, but only contains a casual invitation and a link to Bill Siegel outlines a theory called the 'Control Factor' that frames Islam as a coordinated threa

20p
House OversightOtherNov 11, 2025

Email chain between Lesley Groff, Jeffrey Epstein and Lisa New discussing Poetry in America campaign

The passage contains a routine correspondence about a poetry program and scheduling, with no concrete allegations, financial details, or links to high‑level officials. It mentions Jeffrey Epstein but Jeffrey Epstein is communicating with Lesley Groff and Lisa New about a poetry initiative. Lisa New references a "Templeton campaign" and seeks advice from Epstein. No specific dates, amounts, or ent

1p
House OversightUnknown

Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019)

Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019) The passage provides a market‑focused summary of several publicly traded cannabis/MSO companies and their product expansions. It contains no specific allegations, financial flows, or connections to high‑level officials, but it does mention revenue figures and growth rates that could be useful for baseline industry analysis. Because it lacks any reference to powerful actors, controversial actions, or actionable leads, its investigative value is limited. Key insights: Curaleaf launched a CBD line sold in 47 states, targeting pharmacy chains and grocery stores.; Curaleaf reported ~$45 M revenue for FY9M18 with 247% YoY growth and 57% gross margin.; CV Sciences’ PlusCBD Oi! brand generated ~$34 M revenue FY9M18, 153% YoY growth, 72% gross margin.

1p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01447597

Forwarded by Nav Gupta/db/dbcom on 10/07/2014 17:08 From: vinit To: jeevacation@gmail.com, Cc: Paul Morris/c Nav Gupta Date: 09/07/2014 14:41 Subject: Re: Jeffrey - can we have a quick chat this am ? [C] classification: confidential Hi Jeffrey - looping in Nay and Paul. To recap: we will find a few funds, which we think have best performance characteristic and best fees for u. Loan Funds better than single loans as u don't need to bother booking single loans and servicing them. If

1p
House OversightUnknown

Discovery Dispute Over Alan Dershowitz's Document Control in Defamation Suit

Discovery Dispute Over Alan Dershowitz's Document Control in Defamation Suit The passage outlines a procedural battle over production of documents and metadata in a defamation case involving Alan Dershowitz. While it flags potential evidence that could expose communications or internal materials, it lacks concrete details about the content, dates, or parties beyond the litigants, limiting immediate investigative value. However, the mention of “control” and alleged refusal to produce metadata could merit follow‑up to determine what information is being withheld and whether it relates to broader controversies surrounding Dershowitz. Key insights: Plaintiffs allege Dershowitz is withholding documents and metadata under the claim of ‘control’.; The objection is framed as ‘word play’ and gamesmanship, suggesting possible intentional concealment.; Discovery objections focus on timeframe limits, implying plaintiffs seek records spanning an undefined period.

1p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01394143

GLDUS1 29 OF Enterpnses equity securities, or anyone else who otherwise qualifies as a Covered Person becomes subject to a disqualifying event. The Access Fund will be required to make representations to the Glendower GP that the Access Fund and anyone that is treated as a beneficial owner under Rule 506, has not been subject to a disqualifying event. To the extent that any of the foregoing persons is not able to make such representation, or becomes subject to a disqualifying event, the Gl

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.